The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Open accessPublished version of a preprint
Abstract
C o r r e s p o n d e n c e Protection against the Omicron Variant from Previous SARS-CoV-2 InfectionTo the Editor: Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha), 1,2 B.1.351(beta), 1 and B.1.617.2 (delta) 3 variants.However, the B.1.1.529(omicron) variant harbors multiple mutations that can mediate immune evasion.We estimated the effectiveness of previous infection in preventing symptomatic new cases caused by omicron and other SARS-CoV-2 variants in Qatar.In this study, we extracted data regarding coronavirus disease 2019 (Covid-19) laboratory testing, vaccination, clinical infection data, and related demographic details from the national SARS-CoV-2 databases, which include all results of polymerase-chain-reaction (PCR) testing, vaccinations, and hospitalizations and deaths for Covid-19 in Qatar since the start of the pandemic.The effectiveness of previous SARS-CoV-2 infection in preventing reinfection was defined as the proportional reduction in susceptibility to infection among persons who had recovered from infection as compared with those who had not been infected.4 Previous SARS-CoV-2 infection was defined as a positive result on PCR assay at least 90 days before a new positive PCR finding.4 We used a test-negative, case-control study design to assess the effectiveness of previ-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Accordingly, previous infections in this study were considered to be due to variants other than omicron, since they occurred before the omicron wave in Qatar.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“Of these specimens, 300 (95.2%) were confirmed to be omicron infections and 15 (4.8%) to be delta (or B.1.617.2)1 infections.”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“These findings are explained by the short-lived protection of primary-series vaccination against omicron infections3,27 and the more durable protection from natural infection,2,28 as confirmed by the additional analysis of protection as a function of time after previous infection or vaccination (Figure 3).”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“The results confirmed other findings that we reported recently, including a protection of approximately 50% for previous infection against reinfection with BA.1,2 a protection of approximately 50% for mRNA boosters as compared with primary series,4 and the finding that mRNA vaccines have negligible effectiveness against omicron infection 6 or more months after the second dose.3”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies that used similar methods. These included different adjustments and controls in the analysis and different study inclusion and exclusion criteria to investigate whether effectiveness estimates could have been biased.12,22 These analyses showed consistent findings.2,3,12,17,2”
From Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections (2022) · cites this paper as [2]
In the citing paper
“The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 20222–5.”
From Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar (2022) · cites this paper as [3]
In the citing paper
“One study estimates a protection through previous infection of 92% against Delta and 56% against Omicron. 31”
From Vaccine mandates for healthcare workers beyond COVID-19 (2023) · cites this paper as [31]
In the citing paper
“Now, prior infection does not offer the same level of protection against Omicron as against Delta.”
From Vaccine mandates for healthcare workers beyond COVID-19 (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
Abu-Raddad, L. J., Chemaitelly, H., & Butt, A. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104974 · Cited by 899
Self-citationWaning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Self-citationAnalysis of matched case-control studies
Pearce, N. E. (2016) · BMJ · doi:10.1136/bmj.i969 · Cited by 774
The test-negative design for estimating influenza vaccine effectiveness
Jackson, M. L., & Nelson, J. C. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.053 · Cited by 510
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Self-citationChemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01446-y · Cited by 386
Self-citation(2021) · doi:10.1016/j.eclinm.2021.100861 · Cited by 201
Self-citationAbu-Raddad, L. J., Chemaitelly, H. S., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Kanaani, Z. A., Al‐Khal, A., Al‐Kuwari, E., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1846 · Cited by 176
Self-citationCOVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar
Saththasivam, J., El-Malah, S. S., Gomez, T., Jabbar, K. A., Remanan, R., Krishnankutty, A. K., Ogunbiyi, O. O., Rasool, K., Ashhab, S., Rashkeev, S. N., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145608 · Cited by 150
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–428 of 428
Rodriguez-Idiazabal, L., Fernández, D., Quintana, J. M., García-Asensio, J., Legarreta, M. J., Larrea, N., & Barrio, I. (2025) · Archives of Public Health · doi:10.1186/s13690-025-01681-6
Sawyer, S. L., Warren, C. J., & Barbachano-Guerrero, A. (2022) · doi:10.64628/aai.rg4pj9ndw
What is the new COVID-19 variant BA.2, and will it cause another wave of infections in the US?
Nagarkatti, P. S., & Nagarkatti, M. (2022) · doi:10.64628/aai.p69y6krxk
Zheng, Q., Meng, Q., & Bao, C. (2025) · Risk Analysis · doi:10.1111/risa.70118
A biosocial approach to understanding SARS-CoV-2 seroprevalence in an Orthodox Jewish community
Ismailova, N., Nguyen, A. K. D., Deagle, R. C., Krisna, S. S., Al-Aubodah, T.-A., Mason, H., Schuster, T., Barnett, T. A., Nugus, P., Claudio, F., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e44017
Ayoub, H. H., Chemaitelly, H. S., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Coyle, P. V., Kanaani, Z. A., Al‐Kuwari, E., Kaleeckal, A. H., et al. (2025) · Public Health · doi:10.1016/j.puhe.2025.106016
Self-citationAdditional file 1 of Modelling the impact of hybrid immunity on future COVID-19 epidemic waves
Le, T. P., Abell, I. R., Conway, E. J., Campbell, P. T., Hogan, A. B., Lydeamore, M., McVernon, J., Mueller, I., Walker, C. R., & Baker, C. M. (2024) · Figshare · doi:10.6084/m9.figshare.26707427
Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · Figshare · doi:10.6084/m9.figshare.25001703
Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · Figshare · doi:10.6084/m9.figshare.25001755
Ukwishaka, J., Ndayishimiye, Y., Destine, E., Danwang, C., & Kirakoya-Samadoulougou, F. (2024) · Figshare · doi:10.6084/m9.figshare.26585631
Yamamoto, S., Matsuda, K., Maeda, K., Oshiro, Y., Inamura, N., Mizoue, T., Konishi, M., Takeuchi, J. S., Horii, K., Ozeki, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22767416
Arabi, M., Al-Najjar, Y. A., Sharma, O., Kamal, I., Javed, A., Gohil, H., Paul, P., Al-Khalifa, A. M., Laws, S., & Zakaria, D. (2024) · Figshare · doi:10.6084/m9.figshare.26599849
Du, H., Saiyed, S., & Gardner, L. (2024) · Figshare · doi:10.6084/m9.figshare.26669466
Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · Figshare · doi:10.6084/m9.figshare.26667984
Tan, M. W., Anelone, A. J. N., Tay, A. T., Tan, R. Y., Zeng, K., Tan, K. B., & Clapham, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.26143688
Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · Figshare · doi:10.6084/m9.figshare.26667981
Arabi, M., Al-Najjar, Y. A., Sharma, O., Kamal, I., Javed, A., Gohil, H., Paul, P., Al-Khalifa, A. M., Laws, S., & Zakaria, D. (2024) · Figshare · doi:10.6084/m9.figshare.26599852
Hayashi, K., & Nishiura, H. (2024) · Figshare · doi:10.6084/m9.figshare.26553569
Tan, M. W., Anelone, A. J. N., Tay, A. T., Tan, R. Y., Zeng, K., Tan, K. B., & Clapham, H. E. (2024) · Figshare · doi:10.6084/m9.figshare.26143799
Hayashi, K., & Nishiura, H. (2024) · Figshare · doi:10.6084/m9.figshare.26553572
Bøås, H., Storm, M. L., Tapia, G., Kristoffersen, A. B., Løvlie, A. L., Størdal, K., Lyngstad, T. M., Bragstad, K., Hungnes, O., & Veneti, L. (2024) · Figshare · doi:10.6084/m9.figshare.26667978
Palomares, A. D.-L., de Blasio, B. F., Chan, L. Y. H., Ruscio, F. D., & Midtbø, J. E. (2026) · Epidemics · doi:10.1016/j.epidem.2026.100895
Shyamkumar, R. M., Madiyal, M., Bhuvanagiri, G., Pinto, M. R., Nayak, P. P., & Chopra, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-42177-9
Étude de la réponse humorale lors de l'infection par le SARS-CoV-2
Marot, S. (2023) · theses.fr (ABES) · doi:10.70675/7d41e61azd818z408dzb17cz1c0cf0738b83
Yang, L., Zhou, Z., Lin, Q., Chen, Y., Sun, Y. N., & Wang, Z. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13826-1
Sukik, L., Paul, P., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag210
Self-citationSarcone, A., Deodato, M. R., Pasquale, A. D., Sarro, C. D., Nobile, C. G. A., & Pileggi, C. (2026) · Vaccines · doi:10.3390/vaccines14100852
Metadata
- Authors
- Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., Al-Khal, A., Bertollini, R., Tang, P., & Abu-Raddad, L. J.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Sidra Medicine, Doha, Qatar
- Qatar University (QA)
- Hamad Medical Corporation (QA)
- Primary Health Care (QA)
- Ministry of Public Health (QA)
- Corresponding author
- Abu-Raddad, Laith J.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-03-31
- Volume
- 386
- Issue
- 13
- Pages
- 1288-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8849180
- OpenAlex
- W4211118466
- Cited by
- 445
- References
- 24
- Citations by year
- 2026: 10 · 2025: 32 · 2024: 66 · 2023: 129 · 2022: 208
- FWCI
- 53.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Qatar University QSpace (Qatar University) (submittedVersion)
- Funders
- Qatar Genome Program and Qatar University Biomedical Research Center
- Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine–Qatar
- Qatar Ministry of Public Health; Hamad Medical Corporation; and Sidra Medicine
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- Omicron variant, SARS-CoV-2, natural immunity, prior infection, reinfection prevention, immune evasion, symptomatic COVID-19, test-negative design, Qatar
- MeSH terms
- COVID-19, SARS-CoV-2, Humans, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
